EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Complement activation assessed by C3bc and C5b-9 terminal complex as diagnostic biomarkers for deep vein thrombosis

Vårin Eiriksdatter Wikan iD, Øyvind Øverli, Thor Ueland, Tom Eirik Mollnes, Sigrid Kufaas Brækkan, Annika Elisabet Michelsen, Gholamreza Jafari Yeganeh, John-Bjarne Hansen iD, Ellen Elisabeth Brodin

PLOS One · 2025

DOI: 10.1371/journal.pone.0333206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Vårin Eiriksdatter Wikan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Thrombosis Research Group (TREC), UiT - The Arctic University of Norway, Tromsø, Norway. Hauptthemen laut MEDLINE: Venous Thrombosis, Complement Membrane Attack Complex, Complement Activation, Complement C3b. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The overuse of compression ultrasound procedures on patients with suspected deep vein thrombosis compromise the cost-effectiveness of deep vein thrombosis management and emphasize room for improvement of the current diagnostic algorithm. As the complement system and hemostasis are comprehensively intertwined, we aimed to investigate complement activation products as diagnostic tests for acute deep vein thrombosis alone or together with D-dimer.

Methods

We performed a cross-sectional study using consecutive sampling of outpatients referred to the emergency department with suspected first-time deep vein thrombosis of the lower limbs, to investigate the diagnostic utility of the index tests C3bc and C5b-C9 terminal complex (TCC) with compression ultrasound as reference standard. For comparison of receiver operating characteristics, analyses were also performed for D-dimer and C-reactive protein in addition to analyses for the index tests on a D-dimer positive patient subgroup.

Results

Of the 366 included patients, 103 had deep vein thrombosis. The calculated effect sizes of differences between groups (Cohen’s d) with 95% confidence intervals (95%CI) were 0.25 (95%CI 0.03–0.48) for C3bc, 0.33 (95%CI 0.09–0.57) for C5b-C9 terminal complex (TCC), 0.88 (95%CI 0.61–1.15) for C-reactive protein, and 1.64 (95%CI 1.37–1.91) for D-dimer. The areas under the curves derived from comparison receiver operating characteristics analyses with corresponding 95%CIs for C3bc, C5b-C9 terminal complex (TCC), C-reactive protein and D-dimer were 0.56 (95%CI 0.50–0.63), 0.64 (95%CI 0.58–0.69), 0.73 (95%CI 0.67–0.79) and 0.92 (95%CI 0.89–0.95), respectively.

Conclusion

The plasma levels of the complement activation products C3bc and C5b-C9 terminal complex (TCC) were elevated in patients with acute deep vein thrombosis but displayed low diagnostic performance for deep vein thrombosis alone or together with D-dimer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThrombosisComplement Membrane Attack ComplexComplement ActivationComplement C3bHumansMaleFemaleMiddle AgedBiomarkersCross-Sectional StudiesFibrin Fibrinogen Degradation ProductsAgedAdultC-Reactive ProteinROC Curve

Substanzen

Biomarkersfibrin fragment DFibrin Fibrinogen Degradation ProductsComplement Membrane Attack ComplexComplement C3bC-Reactive Protein

Autor:innen und Institutionen

  • Department of Clinical Medicine, Thrombosis Research Group (TREC), UiT - The Arctic University of Norway, Tromsø, Norway.
  • Hematological Research Group, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Research Institute of Internal Medicine, Oslo University Hospital (Rikshospitalet), Oslo, Norway.
  • Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Research Laboratory, Nordland Hospital, Bodø, Norway.

ORCID-Profile: Vårin Eiriksdatter Wikan, John-Bjarne Hansen

Zitieren

APA

Wikan, V. E., Øverli, Ø., Ueland, T., Mollnes, T. E., Brækkan, S. K., Michelsen, A. E., Yeganeh, G. J., Hansen, J. B., & Brodin, E. E. (2025). Complement activation assessed by C3bc and C5b-9 terminal complex as diagnostic biomarkers for deep vein thrombosis. PLOS One. https://doi.org/10.1371/journal.pone.0333206

Vancouver

Wikan VE, Øverli Ø, Ueland T, Mollnes TE, Brækkan SK, Michelsen AE, et al. Complement activation assessed by C3bc and C5b-9 terminal complex as diagnostic biomarkers for deep vein thrombosis. PLOS One. 2025. doi:10.1371/journal.pone.0333206

BibTeX
@article{Wikan2025,
  author = {Wikan, Vårin Eiriksdatter and Øverli, Øyvind and Ueland, Thor and Mollnes, Tom Eirik and Brækkan, Sigrid Kufaas and Michelsen, Annika Elisabet and Yeganeh, Gholamreza Jafari and Hansen, John-Bjarne and Brodin, Ellen Elisabeth},
  title = {Complement activation assessed by C3bc and C5b-9 terminal complex as diagnostic biomarkers for deep vein thrombosis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0333206}
}
Kostenlos starten →